Abstract
Differences in the degree of trapping of initial block byN-methyl-d-aspartate (NMDA) receptor antagonists may affect their safety and, hence, suitability for clinical trials. In this comparative study, 23 compounds structurally related to the low-affinity, use-dependent NMDA receptor antagonist (S)-α-phenyl-2-pyridineethanamine dihydrochloride (AR-R15896AR) were examined to determine the degree of trapping block they exhibit. Compounds were tested at concentrations that produced a comparable initial 80% block of NMDA-mediated whole-cell current in rat cortical cultures. A wide range of values of trapping block was found, indicating that trapping is not an all-or-none event. Fifteen of the compounds trapped significantly more than the 54 ± 3% of initial block trapped by AR-R15896AR. The off-rates of these compounds were slower than that of AR-R15896AR. Only 2 of the 23 compounds trapped significantly less than AR-R15896AR. AR-R15808, the piperidine analog of AR-R15896AR, appeared to trap only 8 ± 3% of its initial block, although its fast off-rate confounded accurate quantification of trapping. AR-R26952, which, like AR-R15896AR, contains a pyridine in place of a phenyl group, trapped 40 ± 5% of its initial block and exhibited kinetics comparable with AR-R15896AR. Structure-activity analysis suggested that the presence of two basic nitrogen atoms and decreased hydrophobicity led to decreased trapping. There was no correlation between trapping and lipophilicity as would be expected if closed-channel egress was due to escape through the lipid bilayer. However, there was a positive correlation between off-rate and degree of trapping. Models that can account for partial trapping are presented.
Footnotes
-
Send reprint requests to: Geoff Mealing, Institute for Biological Sciences, National Research Council of Canada, Building M54, Montreal Rd., Ottawa, Ontario, Canada K1A 0R6. E-mail:Geoff.Mealing{at}nrc.ca
-
This work was funded by the National Research Council of Canada and AstraZeneca Canada, Inc.
- Abbreviations:
- NMDA
- N-methyl-d-aspartate
- PCP
- phencyclidine
- MK-801
- dizocilpine
- ADCI
- 5-aminocarbonyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine
- AR-R15896AR
- (S)-α-phenyl-2-pyridineethanamine dihydrochloride
- MEM
- Eagle's minimal essential medium
- 9-AA
- 9-aminoacridine
- Received November 17, 2000.
- Accepted February 13, 2001.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|